

## Clinical Guidelines and Related Provider Requirements: Pharmacologic Treatment of Schizophrenia

---

CBH has adopted clinical practice guidelines (CPGs) to outline best practices for the treatment of specific disorders or certain populations. These guidelines will be used by CBH to assess the quality of care provided to CBH members. As such, providers are advised to review and, where appropriate, implement these best practices in their care. CPGs apply to all clinical settings where care is delivered to members. CPGs should be used in conjunction with any level-of-care-specific performance standards, as well as all other required CBH, state, and federal regulations and standards.

CBH has updated the existing guidelines for the pharmacologic treatment of schizophrenia. The most recent version of all CPGs can be found on the [CBH Clinical Practice Guidelines webpage](#).

To ensure alignment and best practices, CBH recommends that providers review the CPGs and make any necessary updates or revisions to provider policies and procedures.

Significant changes to the Pharmacologic Treatment of Schizophrenia CPG include:

- ➔ The removal of Department of Behavioral Health and Intellectual disAbility Services (DBHIDS)/CBH Bulletin 07-07
  - » Replaced with the addition of Appendix 5.6: CBH Policy on the Screening for and Treatment of the Components of Metabolic Syndrome
- ➔ Inclusion of resources related to schizophrenia during pregnancy in Appendix 5.2
- ➔ Updated language in Section 3.1 regarding screening for homicidal ideation
- ➔ Added context in Section 3.8 regarding the removal of the Risk Evaluation and Mitigation Strategies Program (REMS)
- ➔ The addition of National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Informatic Set (HEDIS) performance measure ‘SMC: Cardiovascular Monitoring for People with Cardiovascular Disease and Serious Mental Illness’ as a monitoring metric in Section 4

## Clinical Guidelines and Related Provider Requirements: Pharmacologic Treatment of Schizophrenia

---

Adherence to the CPGs will be assessed through CBH monitoring and oversight, including Quality, Clinical, and Compliance Department protocols. To assess quality of care and align with state and regulatory requirements, CBH will also be utilizing several specific metrics for the CPG, which are detailed in the table below.

Clinical Guidelines	Quality Metrics
<a href="#"><u>Clinical Practice Guidelines for the Pharmacologic Treatment of Schizophrenia</u></a>	<ul style="list-style-type: none"><li>➔ HEDIS SAA: Adherence to Antipsychotic Medications for Individuals with Schizophrenia</li><li>➔ HEDIS SSD: Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications</li><li>➔ HEDIS SMD: Diabetes Monitoring for People with Diabetes and Schizophrenia</li><li>➔ HEDIS SMC: Cardiovascular Monitoring for People with Cardiovascular Disease and Serious Mental Illness</li></ul>

---

These requirements take effect on **June 1, 2025**. Please direct questions regarding *Clinical Practice Guidelines for the Pharmacologic Treatment of Schizophrenia* to [michelle.reece@phila.gov](mailto:michelle.reece@phila.gov).